47例NSCLC-NED患者中,中位年龄61岁(45岁-78岁),男性38例,女性9例; 37例为低分化癌伴NED,10例为中分化癌伴NED; 2例驱动基因阳性(1例为EGFR敏感突变,1例为ALK融合),一线化疗的客观有效率(objective response rate, ORR)为34.5%,中位无进展生存期(progression-free survival, PFS)为4个月; 整体中位总生存期(overall survival, OS)为11个月,OS超过2年者仅2例(4.2%, 2/47)。. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.